Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial
Posted inCardiology Clinical Updates Neurology news Respiratory

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial

The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective of cardiovascular disease status.
Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study
Posted inInfectious Diseases news Pediatrics

Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study

A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited reactions in adolescents.
Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation
Posted inClinical Updates Infectious Diseases news Public Health Respiratory

Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation

This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the clinical impact of high-dose adjuvanted vaccines.
High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence
Posted inCardiology Public Health Specialties

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence

This review synthesizes evidence on high-dose versus standard-dose influenza vaccines for cardiovascular outcomes in older adults, focusing on the large DANFLU-2 trial and complementary studies, highlighting modest cardiovascular benefits and implications for clinical practice.
High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial
Posted inClinical Updates Internal Medicine news Public Health Respiratory Specialties

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial

The DANFLU-2 trial demonstrates that high-dose influenza vaccine reduces cardiovascular and cardiorespiratory hospitalizations compared to standard-dose in adults ≥65 years, with similar benefits across subgroups including heart failure and atherosclerotic cardiovascular disease.